Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.
复制标题
DOI:
10.3390/pathogens11111259
复制
发表时间:
2022-10-29
期刊:
影响因子:
--
通讯作者:
Reed SG
中科院分区:
文献类型:
--
作者:
Duthie MS;Machado BAS;Badaró R;Kaye PM;Reed SG
Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that could be used to more efficiently evaluate Leishmania vaccine efficacy, including controlled human infection models and initial use in a therapeutic setting, that could prioritize candidates before evaluation in larger, longer and more complicated field trials.
登录
查看更多内容
DOI:
10.4049/jimmunol.1301810
发表时间:
2013-12-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Esch KJ;Juelsgaard R;Martinez PA;Jones DE;Petersen CA
通讯作者:
Petersen CA
影响因子:
5.8
作者:
Coler, Rhea N.;Duthie, Malcolm S.;Reed, Steven G.
通讯作者:
Reed, Steven G.
影响因子:
6.4
作者:
Eyal, Nir;Lipsitch, Marc;Smith, Peter G.
通讯作者:
Smith, Peter G.
DOI:
10.1016/s0035-9203(01)90168-3
发表时间:
2001-03-01
影响因子:
2.2
作者:
Brito, MEF;Mendonça, MG;Abath, FGC
通讯作者:
Abath, FGC
影响因子:
30.5
作者:
Brasu, Nadia;Elia, Ines;Pace, Luigia
通讯作者:
Pace, Luigia